Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXOZYMES INC.EXOZ · Entity 1147 | Chief Executive Officer | August 19, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXOZYMES INC.
Report date August 19, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,708 |
Reported balance
After 2026-08-26 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-08-26 · Purchase · Acquired 4 · Balance 14,708 |
| Common StockSEC Table I · non-derivative | Direct | 14,704 |
Reported balance
After 2026-08-26 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-08-26 · Purchase · Acquired 251 · Balance 14,704 |
| Common StockSEC Table I · non-derivative | Direct | 14,453 |
Reported balance
After 2026-08-26 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-08-26 · Purchase · Acquired 250 · Balance 14,453 |
| Common StockSEC Table I · non-derivative | Direct | 14,203 |
Reported balance
After 2026-08-25 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-08-25 · Purchase · Acquired 250 · Balance 14,203 |
| Common StockSEC Table I · non-derivative | Direct | 13,953 |
Reported balance
After 2026-08-25 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2026-08-25 · Purchase · Acquired 100 · Balance 13,953 |
| Common StockSEC Table I · non-derivative | Direct | 13,853 |
Reported balance
After 2026-08-19 transaction · row 6
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 6 · 2026-08-19 · Grant · Acquired 8,841 · Balance 13,853 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2026 Filed Sep 2, 2026 23:33 UTC | EXOZYMES INC. EXOZ · Entity 1147 | PurchaseCommon Stock | 250 | $7.60 | $1,900.00 |
DisclosureSEC source: 0001493152-26-041290 · ownership.xml · nonDerivative · entry 3 Heltzen Michael · CIK 0002030840 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,453 Read SEC document |
| August 26, 2026 Filed Sep 2, 2026 23:33 UTC | EXOZYMES INC. EXOZ · Entity 1147 | PurchaseCommon Stock | 251 | $7.35 | $1,844.85 |
DisclosureSEC source: 0001493152-26-041290 · ownership.xml · nonDerivative · entry 2 Heltzen Michael · CIK 0002030840 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,704 Read SEC document |
| August 26, 2026 Filed Sep 2, 2026 23:33 UTC | EXOZYMES INC. EXOZ · Entity 1147 | PurchaseCommon Stock | 4 | $7.58 | $30.32 |
DisclosureSEC source: 0001493152-26-041290 · ownership.xml · nonDerivative · entry 1 Heltzen Michael · CIK 0002030840 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,708 Read SEC document |
| August 25, 2026 Filed Sep 2, 2026 23:33 UTC | EXOZYMES INC. EXOZ · Entity 1147 | PurchaseCommon Stock | 100 | $7.50 | $750.00 |
DisclosureSEC source: 0001493152-26-041290 · ownership.xml · nonDerivative · entry 5 Heltzen Michael · CIK 0002030840 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,953 Read SEC document |
| August 25, 2026 Filed Sep 2, 2026 23:33 UTC | EXOZYMES INC. EXOZ · Entity 1147 | PurchaseCommon Stock | 250 | $7.52 | $1,880.00 |
DisclosureSEC source: 0001493152-26-041290 · ownership.xml · nonDerivative · entry 4 Heltzen Michael · CIK 0002030840 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,203 Read SEC document |
| August 19, 2026 Filed Sep 2, 2026 23:33 UTC | EXOZYMES INC. EXOZ · Entity 1147 | GrantCommon Stock | 8,841 | $6.40 | $56,582.40 |
DisclosureSEC source: 0001493152-26-041290 · ownership.xml · nonDerivative · entry 6 Heltzen Michael · CIK 0002030840 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,853 Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 17:49 UTC | EXOZYMES INC. EXOZ · Entity 1147 | PurchaseCommon Stock | 1,040 | $10.22 | $10,628.80 |
DisclosureSEC source: 0001641172-25-017630 · ownership.xml · nonDerivative · entry 1 Heltzen Michael · CIK 0002030840 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,628.8 Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 12:31 UTC | EXOZYMES INC. EXOZ · Entity 1147 | GrantStock Options for Common Stock · Derivative | 235,817 | $0.00 Strike: $12.40 | $0.00 |
DisclosureSEC source: 0001641172-25-015778 · ownership.xml · derivative · entry 1 Heltzen Michael · CIK 0002030840 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,817 Underlying: Common Stock · 235,817 shares Expires 2032-06-29 F1 · security: The Options will vest over a four (4) year period, in equal quarterly installments at the end of each quarter of the calendar year, and the Options will commence vesting on July 1, 2025.The option expires June 29, 2032. Read SEC document |
| January 17, 2025 Filed Jan 21, 2025 06:02 UTC | EXOZYMES INC. IZTC · Entity 1147 | PurchaseCommon Stock | 1,767 | $10.78 | $19,048.26 |
DisclosureSEC source: 0001493152-25-002875 · ownership.xml · nonDerivative · entry 2 Heltzen Michael · CIK 0002030840 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,872 F1 · price: The reported price in Column 4 is a weighted average purchase price. The shares acquired on January 17, 2025 were purchased in multiple transactions at prices ranging from $10.45 to $11.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 06:02 UTC | EXOZYMES INC. IZTC · Entity 1147 | PurchaseCommon Stock | 121 | $10.72 | $1,297.12 |
DisclosureSEC source: 0001493152-25-002875 · ownership.xml · nonDerivative · entry 1 Heltzen Michael · CIK 0002030840 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,105 Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 18:45 UTC | EXOZYMES INC. IZTC · Entity 1147 | PurchaseCommon Stock | 1,984 | $11.10 | $22,022.40 |
DisclosureSEC source: 0001493152-24-046902 · ownership.xml · nonDerivative · entry 1 Heltzen Michael · CIK 0002030840 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,984 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.